All articles by Chia Lin
Chia Lin
Reform in South Korea means progression in improving time to reimbursement
According to an RSA report done by the Seoul National University R&DB Research Foundation, the insurance coverage of cancer drugs and rare disease treatments has increased.
Over 2,000 drugs in Japan undergo an average price reduction of 9.4% in April
Historically, Japan performs scheduled biannual price adjustments as a cost-reduction method.
Warnings for Japanese pharmaceutical market may lead to more lenient price controls
The OPIR report showed that Japan’s pricing policy has raised serious concern among large multinational pharmaceutical companies.